[1]王朕华** 张珂① 王悦 井佳雨 张艳 刘梁.保留生育功能法治疗年轻早期高分化子宫内膜癌和复杂性不典型增生[J].中国微创外科杂志,2020,01(8):704-707.
　Wang Zhenhua*,Zhang Ke,Wang Yue*,et al.Fertilitysparing Treatment for Young Patients With Early Stage Well Differentiated Endometrial Cancer or Complex Atypical Hyperplasia[J].Chinese Journal of Minimally Invasive Surgery,2020,01(8):704-707.
点击复制

保留生育功能法治疗年轻早期高分化子宫内膜癌和复杂性不典型增生()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2020年8期
页码:
704-707
栏目:
临床研究
出版日期:
2020-08-25

文章信息/Info

Title:
Fertilitysparing Treatment for Young Patients With Early Stage Well Differentiated Endometrial Cancer or Complex Atypical Hyperplasia
作者:
王朕华** 张珂① 王悦 井佳雨 张艳 刘梁
（河南省人民医院妇科，郑州450003）
Author(s):
Wang Zhenhua*;  Zhang Ke;  Wang Yue*;  et al.
*Department of Obstetrics and Gynecology, Henan Provincial People’s Hospital, Zhengzhou 450003, China
关键词:
子宫内膜癌; 保留生育功能
Keywords:
Endometrial carcinoma; Fertilitysparing treatment
文献标志码:
A
摘要:
目的探讨宫腔镜病灶切除、促性腺激素释放激素类似物（GnRHa）联合左炔诺孕酮宫内节育系统（曼月乐）或来曲唑治疗早期高分化子宫内膜癌和复杂性不典型增生的年轻患者的有效性和安全性。方法对2013年1月~2018年10月34例小于42岁的早期高分化子宫内膜腺癌（局限于黏膜内，无明显肌层侵犯，16例）或复杂性不典型增生（18例），行宫腔镜双极电刀病灶切除术，术后戈舍瑞林3.75 mg皮下注射28天一次共3次。19例手术结束时置入曼月乐，另15例术后口服来曲唑2.5 mg每天一次。所有患者每隔3个月复查阴道超声、宫腔镜诊刮术。结果随访9~68个月，平均34.6月。完全反应率子宫内膜癌为87.5%（14/16），复杂性不典型增生为100%（18/18）；疾病稳定2例，均为子宫内膜癌。完全反应的子宫内膜癌和复杂性不典型增生各有1例复发。2例复发和2例疾病稳定者均行子宫切除术。随访期间11例获得12次妊娠。结论宫腔镜病灶切除、GnRHa联合曼月乐或来曲唑的保留生育功能方法治疗早期高分化子宫内膜癌和复杂性不典型增生安全、有效。完成生育后应该行子宫切除，尤其子宫内膜癌患者。
Abstract:
ObjectiveTo evaluate the efficacy and safety of hysteroscopic lesionectomy and gonadotropinreleasing hormone agonist (GnRHa) combined with levonorgestrelreleasing intrauterine system (Mirena) or letrozole in young women with early stage welldifferentiated endometrial carcinoma (EC) or complex atypical hyperplasia (CAH).MethodsWe performed a retrospective analysis on the clinical characteristics of 34 patients younger than 42 years old with early stage welldifferentiated EC (localized in the mucosa without obvious muscularis invasion, 16 cases) or CAH (18 cases) from January 2013 to October 2018. All the patients underwent hysteroscopic bipolar electrosurgical resection, and received goserelin 3.75 mg subcutaneous injection once every 28 days for 3 times. A total of 19 cases were treated with Mirena at the end of the operation, while the other 15 cases were given letrozole 2.5 mg once a day. All the patients underwent followups with endometrial sampling by hysteroscopy and curettage and transvaginal ultrasound (TVS) for every 3 months.ResultsThe patients were followed up for 9-68 months (mean, 34.6 months). The complete response(CR) rate of EC was 87.5% (14/16) and that of CAH was 100% (18/18); the disease was stable in 2 cases, both of which were endometrial carcinoma. Among the women who achieved CR, 1 case of CAH and 1 case of EC had relapsed. Hysterectomy was performed in 2 patients with recurrence and 2 patients with stable disease. During the followup period, 11 cases got 12 pregnancies.ConclusionsHysteroscopic lesionectomy and GnRHa combined with levonorgestrel intrauterine hormonal system or letrozole is an effective fertilitysparing strategy for young women with early stage welldifferentiated EC or CAH. Hysterectomy should be performed after childbirth, especially in patients with EC.

参考文献/References:

[1]Tock S,Jadoul P,Squifflet JL,et al.Fertility sparing treatment in patients with early stage endometrial cancer,using a combination of surgery and GnRH agonist:a monocentric retrospective study and review of the literature.Front Med (Lausanne),2018,5:240.
[2]Park JY,Kim DY,Kim JH,et al.Longterm oncologic outcomes after fertilitysparing management using oral progestin for young women with endometrial cancer (KGOG 2002).Eur J Cancer,2013,49(4):868-874.
[3]Shan BE,Ren YL,Sun JM,et al.A prospective study of fertilitysparing treatment with megestrol acetate following hysteroscopic curettage for welldifferentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet,2013,288(5):1115-1123.
[4]林仲秋,谢玲玲,林荣春.《2016 NCCN子宫肿瘤临床实践指南》解读.中国实用妇科与产科杂志,2016,32(2):117-122.
[5]Wang Q,Guo Q,Gao S,et al.Fertilityconservation combined therapy with hysteroscopic resection and oral progesterone for local early stage endometrial carcinoma in young women.Int J Clin Exp Med,2015,8:13804-13810.
[6]Inoue O,Hamatani T,Susumu N,et al.Factors affecting pregnancy outcomes in young women treated with fertilitypreserving therapy for welldifferentiated endometrial cancer or atypical endometrial hyperplasia.Reprod Biol Endocrinol,2016,14:2.
[7]Koh WJ,AbuRustum NR,Bean S,et al.Uterine neoplasms,version 1.2018,NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw,2018,16(2):170-199.
[8]Rodolakis A,Biliatis I,Morice P,et al.European society of gynecological oncology task force for fertility preservation: clinical recommendations for fertilitysparing management in young endometrial cancer patients.Int J Gynecol Cancer,2015,25(7):1258-1265.
[9]中华医学会妇科肿瘤学分会.妇科恶性肿瘤保留生育功能临床诊治指南.中华妇产科杂志,2014,49(4):243-248.
[10]中国研究型医院学会妇产科专业委员会.早期子宫内膜癌保留生育功能治疗专家共识.临床医学研究与实践,2019,4(23):封3.
[11]Zhou H,Cao D,Yang J,et al.Gonadotropinreleasing hormone agonist combined with a levonorgestrelreleasing intrauterine system or letrozole for fertilitypreserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women.Int J Gynecol Cancer,2017,27(6):1178-1182.

备注/Memo

备注/Memo:
基金项目：河南省科技厅科技攻关项目（162102310022）；河南省高等学校重点科研项目计划（13A320639）；河南省医学科技攻关计划项目（201203120）**通讯作者，Email：wzh0371@163.com ①（河南省许昌市人民医院妇科，许昌461000）
更新日期/Last Update: 2020-11-13